You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 2, February 1963 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Control of Anticoagulant Therapy

Progress and Problems blems

ARMAND J. QUICK, M.D.

Arch Intern Med. 1963;111(2):234-239.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The one-stage prothrombin time was intimately associated with the development of oral anticoagulant therapy. As Link has stated: "Through it the hemorrhagic agent of spoiled sweet clover hay was laid out on the table in pure crystalline form." Furthermore, without this simple test, the introduction of bishydroxycoumarin (Dicumarol) into therapy would have been exceedingly hazardous. In the early studies,1 the increased prothrombin time was regarded as a depression solely of prothrombin, and this assumption was supported by the finding that the 2-stage method of Warner, Brinkhous, and Smith2 likewise showed a marked decrease of prothrombin when bishydroxycoumarin was given. The discoveries of Factor V (labile factor) in 1943,3 and of a serum agent (Factor VII) a few years later,4,5 made it evident that neither method measured prothrombin specifically. It was the one-stage test, however, which has received most of the criticism and been subjected to numerous . . . [Full Text PDF of this Article]


Author Affiliations

MILWAUKEE

From Department of Biochemistry, Marquette University School of Medicine.


Footnotes

Received for publication Sept. 4, 1962. Accepted Oct. 5.

Read before the Joint Meeting on Anticoagulant and Thrombolytic Therapy with the American Heart Association at the 111th Annual Meeting of the American Medical Association, Chicago, June 26, 1962.

Supported by a grant from the American Heart Association.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1963 American Medical Association. All Rights Reserved.